Optimization of propafenone analogues as antimalarial leads.

Article Details

Citation

Copy to clipboard

Lowes DJ, Guiguemde WA, Connelly MC, Zhu F, Sigal MS, Clark JA, Lemoff AS, Derisi JL, Wilson EB, Guy RK

Optimization of propafenone analogues as antimalarial leads.

J Med Chem. 2011 Nov 10;54(21):7477-85. doi: 10.1021/jm2005546. Epub 2011 Oct 10.

PubMed ID

21955244 [ View in PubMed

]

Abstract

Propafenone, a class Ic antiarrythmic drug, inhibits growth of cultured Plasmodium falciparum. While the drug's potency is significant, further development of propafenone as an antimalarial would require divorcing the antimalarial and cardiac activities as well as improving the pharmacokinetic profile of the drug. A small array of propafenone analogues was designed and synthesized to address the cardiac ion channel and PK liabilities. Testing of this array revealed potent inhibitors of the 3D7 (drug sensitive) and K1 (drug resistant) strains of P. falciparum that possessed significantly reduced ion channel effects and improved metabolic stability. Propafenone analogues are unusual among antimalarial leads in that they are more potent against the multidrug resistant K1 strain of P. falciparum compared to the 3D7 strain.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Propafenone	Potassium voltage-gated channel subfamily H member 2	IC 50 (nM)	2880	N/A	N/A	Details
Propafenone	Sodium channel protein type 5 subunit alpha	IC 50 (nM)	3300	N/A	N/A	Details
Propafenone	Sodium channel protein type 5 subunit alpha	IC 50 (nM)	>5000	N/A	N/A	Details